The analysis of patients with primary and secondary glomerular diseases: A single-center experience

Ayar, Yavuz; Isiktas, Emel; Ocakoğlu, Gökhan; Yıldız, Abdülmecit; Oruç, Ayşegül; Demirayak, Dilay; Bayrakçı, İsmail; Duger, Hakan; Bozbudak, Tugba

doi:10.1016/j.hkjn.2016.05.001

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results were mainly driven by the presence of systemic amyloidosis, (55%) as the most common SGD, which is resistant to most therapies. [ 17 ] Complete remission rates of SGD's were higher in our series and were mainly attributed to LN and PIGN. The difference in our results may be due to the nature of diseases and available therapies.…”

Section: Discussionmentioning

confidence: 56%

Short term outcome of patients attending a renal-immunology clinic in central India

Atlani

Kapoor

Joshi

et al. 2022

Journal of Postgraduate Medicine

View full text Add to dashboard Cite

Background: Glomerular diseases (GDs) and other renal immunologic diseases are an important cause of morbidity and mortality. Providing a single point of service in collaboration with various specialists at a renal immunology clinic for such patients is not novel, but outcomes have not been reported. Here, we report the short-term outcome of Indian patients attending our clinic. Methods: This single-center prospective cohort study enrolled biopsy-proven immunologically-mediated adults with renal diseases between April 2018 and December 2019, and followed them for six months. The primary end point for the analysis was an incidence of end-stage renal disease (ESRD) or loss of >50% estimated glomerular filtration rate (eGFR) and patient survival at six months. Secondary endpoints were the rate of complete or partial remission, and impact of demographic factors. Results: Ninety two patients underwent renal biopsy for suspected immunological renal diseases. Fourteen (15.2%) cases were excluded for nonimmune etiologies, whereas 78 (84.7%) confirmed cases of immune etiology were included. Most common primary GD (n = 51) (93.5%) was membranous nephropathy (n = 20) (25.6%), whereas lupus nephritis was the most common (n = 8) (29.6%) secondary GD. Overall, 10 (12.8%) patients reached renal endpoint of ESRD or >50% fall in eGFR. Focal segmental glomerulosclerosis (FSGS) (27%) patients had worst renal outcome. Patient survival was 94.8%. Thirty patients (38.4%) achieved complete, whereas 24 each (30.7%) achieved partial remission and remained resistant to disease specific therapies, respectively. Univariate analysis identified hypertension, severity of hypertension, and resistance to achieve proteinuria remission as significantly associated ( P < 0.001) factors with poor renal outcome. Conclusions: The present study shows that short term renal outcome of Indian patients with renal immune diseases remains poor. FSGS remains the GD with the worst renal outcome. Hypertension, its severity, failure to achieve proteinuria remission were significantly associated with poor renal outcomes.

show abstract

Section: Discussionmentioning

confidence: 56%

Short term outcome of patients attending a renal-immunology clinic in central India

Atlani

Kapoor

Joshi

et al. 2022

Journal of Postgraduate Medicine

View full text Add to dashboard Cite

show abstract

“…Glomerular diseases (glomerulopathies) (GDs) are a heterogeneous group of disorders characterized by pathological alterations in glomerular structure and function. GDs may be diagnosed as primary if they are limited solely to the kidney, e.g., IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranous nephropathy (MN), and membranous proliferative glomerulonephritis (MPGN), or as secondary if they are a manifestation of systemic disease, such as diabetes, hypertension, amyloidosis, vasculitis, or lupus (e.g., diabetic kidney disease, secondary FSGS, secondary IgAN, lupus nephropathy) [ 35 ]. Glomerulopathies are the commonest cause of chronic kidney disease (CKD) and, in consequence, end-stage renal failure (end-stage renal disease, ESRD) worldwide.…”

Section: Resultsmentioning

confidence: 99%

The Clinical Significance of Urinary Retinol-Binding Protein 4: A Review

Ratajczyk

Konieczny

Czekaj

et al. 2022

IJERPH

View full text Add to dashboard Cite

Effective biomarkers for early diagnosis, prognostication, and monitoring in renal diseases (in general) comprise an unmet need. Urinary retinol-binding protein 4, which is the most sensitive indicator of renal tubular damage, holds great promise as a universal biomarker for renal pathologies, in which tubular injury is the driving force. Here, we summarize the most important existing data on the associations between urinary retinol-binding protein 4 and renal diseases and highlight the untapped potential of retinol-binding protein 4 in clinical use.

show abstract

“…IgA nephropathy is a glomerular disease that can be recognised only by histopathological examination of the renal biopsy specimen, which reveals the presence of dominant or codominant mesangial deposits of IgA immunoglobulin [ 13 ]. The disease can be diagnosed as primary if it is confined only to the kidney or secondary if it comprises a renal manifestation of a systemic disease, like chronic liver disease, diabetes, hypertension, amyloidosis, or lupus [ 14 ]. IgAN remains the dominant form of primary glomerulopathies in adults, with a global prevalence of 2.5 cases per 100,000 per year [ 15 ].…”

Section: Iga Nephropathymentioning

confidence: 99%

Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?

et al. 2018

View full text Add to dashboard Cite

Early detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge. Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis. It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would improve the clinical care and outcome of patients suffering from IgAN. This review summarises the findings from previous mass spectrometry- (MS-) based studies dedicated to the discovery of urinary peptide profiles specific to IgAN. There is a substantial number of urinary peptides that have been discovered to date, which show promise as biomarkers of IgAN; however, all of them require further, rigorous validation in well-planned studies, involving a large number of subjects who represent diverse and numerous populations.

show abstract

The analysis of patients with primary and secondary glomerular diseases: A single-center experience

Cited by 6 publications

References 23 publications

Short term outcome of patients attending a renal-immunology clinic in central India

Short term outcome of patients attending a renal-immunology clinic in central India

The Clinical Significance of Urinary Retinol-Binding Protein 4: A Review

Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?

Contact Info

Product

Resources

About